Nevertheless, over the last two decades, as agents that target HER2, including trastuzumab and pertuzumab, are extensively applied in clinical practice, significant advances have been made in the treatment of HER2+ BC and overall survival has improved [10,11,12]. The gene discussed is ERBB2; the disease is breast cancer.